{"company":{"id":1949959,"name":"Sarepta","domain":"sarepta.com","url":"https://alion.io/company/sarepta"},"answer":"As of Nov 16, 2026, Alion lists 10 companies most like Sarepta: PTC Therapeutics, Intellia Therapeutics, MeiraGTx, Alnylam, BioMarin Pharmaceutical Inc., Vertex Pharmaceuticals, Rocket Pharmaceuticals, Tessera Therapeutics, Genetixbiotx and Alltrna.","highlights":["Sarepta itself has 9 open roles on Alion.","Of them, Vertex Pharmaceuticals is hiring the most, with 226 open roles.","Tessera Therapeutics has raised the most venture funding on record: $230M.","Open roles at Alnylam fell the most: from 101 on Oct 19, 2026 to 93 now."],"as_of":"2026-11-16","cite":"Alion, \"Sarepta competitors and alternatives: 10 similar companies compared on hiring and funding\", as of Nov 16, 2026. https://alion.io/company/sarepta/competitors","indexable":true,"target":{"name":"Sarepta","url":"https://alion.io/company/sarepta","domain":"sarepta.com","open_roles":9,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"501-1000","headquarters":{"city":"Cambridge","country":"US"},"technologies":["GCP","Veeva","GLP"],"hiring_countries":["US"],"similarity":null},"competitors":[{"name":"PTC Therapeutics","url":"https://alion.io/company/ptcbio","domain":"ptcbio.com","open_roles":25,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"201-500","headquarters":{"city":"Warren","country":"US"},"technologies":["GCP","GMP","Microsoft Excel"],"hiring_countries":["US","IE","JP"],"similarity":{"score":17.8,"shared_segments":["Rare Disease Therapeutics","Cell & Gene Therapy"],"shared_technologies":["GCP","Microsoft Excel","ELISA","GMP","GLP"],"same_hq_country":true}},{"name":"Intellia Therapeutics","url":"https://alion.io/company/intelliatx","domain":"intelliatx.com","open_roles":3,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"501-1000","headquarters":{"city":"Cambridge","country":"US"},"technologies":["Mandiant capa","Digital Twin","GMP"],"hiring_countries":["US"],"similarity":{"score":17.05,"shared_segments":["Cell & Gene Therapy","Rare Disease Therapeutics"],"shared_technologies":["GCP","AI Agents","Microsoft Excel","GMP","Good Clinical Practice"],"same_hq_country":true}},{"name":"MeiraGTx","url":"https://alion.io/company/meiragtx","domain":"meiragtx.com","open_roles":6,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"201-500","headquarters":{"city":"New York","country":"US"},"technologies":["CAPA","GMP","GCP"],"hiring_countries":["GB","US"],"similarity":{"score":17,"shared_segments":["Rare Disease Therapeutics","Cell & Gene Therapy"],"shared_technologies":["GCP","ELISA","GMP","GLP","CAPA"],"same_hq_country":true}},{"name":"Alnylam","url":"https://alion.io/company/alnylam","domain":"alnylam.com","open_roles":93,"open_roles_change":{"since":"2026-10-19","from":101,"to":93,"pct":-8},"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"1001-5000","headquarters":{"city":"Cambridge","country":"US"},"technologies":["Python","GCP","AWS"],"hiring_countries":["US","GB","DE"],"similarity":{"score":16.57,"shared_segments":["Cell & Gene Therapy","Rare Disease Therapeutics"],"shared_technologies":["Copilot","GCP","AI Agents","Microsoft Excel","ELISA"],"same_hq_country":true}},{"name":"BioMarin Pharmaceutical Inc.","url":"https://alion.io/company/biomarin-pharmaceutical-inc","domain":"biomarin.com","open_roles":57,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"501-1000","headquarters":{"city":"San Rafael","country":"US"},"technologies":["GMP","Microsoft Excel","CAPA"],"hiring_countries":["US","IE","GB"],"similarity":{"score":16.55,"shared_segments":["Rare Disease Therapeutics","Cell & Gene Therapy"],"shared_technologies":["Copilot","Microsoft Excel","GMP","GLP","Good Clinical Practice"],"same_hq_country":true}},{"name":"Vertex Pharmaceuticals","url":"https://alion.io/company/vrtx","domain":"vrtx.com","open_roles":226,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"5000+","headquarters":{"city":"Boston","country":"US"},"technologies":["GCP","AI Agents","Python"],"hiring_countries":["US","GB","DE"],"similarity":{"score":16.22,"shared_segments":["Rare Disease Therapeutics","Cell & Gene Therapy"],"shared_technologies":["Copilot","GCP","AI Agents","Microsoft Excel","ELISA"],"same_hq_country":true}},{"name":"Rocket Pharmaceuticals","url":"https://alion.io/company/rocketpharma","domain":"rocketpharma.com","open_roles":6,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"201-500","headquarters":{"city":"Cranbury","country":"US"},"technologies":["CAPA","GMP","Microsoft Excel"],"hiring_countries":["US"],"similarity":{"score":15.5,"shared_segments":["Cell & Gene Therapy","Rare Disease Therapeutics"],"shared_technologies":["Microsoft Excel","ELISA","GMP","Veeva","CAPA"],"same_hq_country":true}},{"name":"Tessera Therapeutics","url":"https://alion.io/company/tesseratherapeutics","domain":"tesseratherapeutics.com","open_roles":4,"open_roles_change":null,"funding":{"total_raised_usd":230000000,"last_round":"venture","last_round_usd":230000000,"last_round_date":"2021-05-20","lead_investors":[]},"size_band":"51-200","headquarters":{"city":"Somerville","country":"US"},"technologies":["GCP","Dagster","AWS"],"hiring_countries":["US"],"similarity":{"score":14.95,"shared_segments":["Rare Disease Therapeutics","Cell & Gene Therapy"],"shared_technologies":["GCP","AI Agents","GMP"],"same_hq_country":true}},{"name":"Genetixbiotx","url":"https://alion.io/company/genetixbiotx-2","domain":"genetixbiotx.com","open_roles":11,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"51-200","headquarters":{"city":"Somerville","country":"US"},"technologies":["CAPA","Microsoft Excel","GMP"],"hiring_countries":["US"],"similarity":{"score":14.75,"shared_segments":["Cell & Gene Therapy","Rare Disease Therapeutics"],"shared_technologies":["Microsoft Excel","ELISA","GMP","Veeva","CAPA"],"same_hq_country":true}},{"name":"Alltrna","url":"https://alion.io/company/alltrna","domain":"alltrna.com","open_roles":3,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"51-200","headquarters":{"city":"Cambridge","country":"US"},"technologies":["GCP","Next-Generation Sequencing","Mass Spectrometry"],"hiring_countries":["US"],"similarity":{"score":13.55,"shared_segments":["Cell & Gene Therapy","Rare Disease Therapeutics"],"shared_technologies":["GCP","GLP"],"same_hq_country":true}}],"method":"Ranked by Alion's similar-companies engine (the MCP tool similar_companies): shared industry segments and the overlap of the two segment sets, technologies named in both companies' job postings, the same headquarters country, a size band near it. Open roles are the visible postings on Alion today; their change is shown only for boards that state posting dates.","html_url":"https://alion.io/company/sarepta/competitors","json_url":"https://alion.io/company/sarepta/competitors.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","built_at":"2026-11-16T03:07:55Z","generated_at":"2026-11-18T19:24:51Z"}}